HPV Infections Clinical Trial
Official title:
A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women
A study to test the safety and effectiveness of Quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine against combined incidence of HPV 6/11/16/18-related persistent infection and vaccine type-specific genital disease among Chinese females between the ages of 20 and 45.
The Base Study V501-041 duration was 30 months. The study was extended to further evaluate the efficacy of Quadrivalent HPV (Type 6, 11, 16, 18) L1 VLP (qHPV) vaccine against Cervical Intraepithelial Neoplasia Grade 2 (CIN 2), CIN 3, Adenocarcinoma In Situ (AIS), and/or cervical cancer. The efficacy was followed through the Month 78 visit, and the close-out visit was conducted at approximately Month 90 with only safety data collected ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00956553 -
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
|
Phase 4 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Suspended |
NCT00733122 -
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
|
Phase 3 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Completed |
NCT03900572 -
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00635830 -
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
|
Phase 1 | |
Not yet recruiting |
NCT01021904 -
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
|
Phase 4 | |
Completed |
NCT00378560 -
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
|
Phase 2 | |
Completed |
NCT00682812 -
Significance of the High-risk Hpv Viral Load
|
N/A | |
Completed |
NCT01086709 -
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
|
||
Completed |
NCT00711815 -
A Study to Identify Markers in Blood and Tissue of HPV Clearance
|
N/A | |
Completed |
NCT03085381 -
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00847340 -
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population
|
N/A | |
Completed |
NCT00411749 -
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
|
Phase 2 | |
Completed |
NCT00943722 -
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
|
Phase 3 |